Form 4: Gabelli Healthcare Director Sells GRX Shares

A director of Gabelli Healthcare & WellnessRx Trust reported multiple pre-scheduled sales of common shares totaling 9,000 units in late 2025.

Summary

• Anthonie C. Van Ekris, a Director of Gabelli Healthcare & WellnessRx Trust (GRX), reported the sale of 9,000 common shares.
• The sales occurred in multiple transactions between August 6, 2025, and October 14, 2025.
• The shares were sold at prices ranging from $9.1198 to $9.5 per share.
• These transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
• Following these transactions, the director beneficially owns 2,185 common shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While director selling can be perceived negatively, the transactions were pre-planned under a Rule 10b5-1(c) plan, mitigating the implication of a sudden loss of confidence. The total number of shares sold is also relatively small in the context of a publicly traded company.

Positives

• NA

Negatives

• A director reduced their direct beneficial ownership in the company by 9,000 common shares, which could be perceived as a slight negative signal by some investors, despite being pre-planned.

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends. Insider sales, especially those under a 10b5-1 plan, are common and do not inherently reflect on the overall health or trends within the healthcare and wellness industry.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The sale of shares by a director could lead to minor concerns about insider confidence, though the pre-planned nature of the sales under Rule 10b5-1(c) typically lessens such concerns.

Next Steps

• NA

Key Dates

Recommendation

The reported sales by a director are part of a pre-planned trading arrangement (Rule 10b5-1(c)) and represent a relatively small portion of the company's outstanding shares. While insider selling can sometimes signal a lack of confidence, these transactions alone do not provide sufficient grounds for a change in investment recommendation for the broader market. The fundamental outlook for Gabelli Healthcare & WellnessRx Trust remains unchanged based solely on this Form 4 filing.

Keywords

Gabelli Healthcare & WellnessRx Trust, GRX, Form 4, insider trading, director sales, common shares, Rule 10b5-1 plan